PDC-APB

PDC-APB, or 3-pentadecyl-1,2-phenylene bis(4-(4-aminophenyl)butanoate),^[1] is a drug candidate under evaluation to determine if it might protect against contact dermatitis caused by urishiol from poison ivy, poison oak, and poison sumac.^[2][3][4]

PDC-APB

Clinical data
Other names	3-Pentadecyl-1,2-phenylene bis(4-(4-aminophenyl)butanoate; Benzenebutanoic acid, 4-amino-, 1,1'-(3-pentadecyl-1,2-phenylene) ester
Identifiers
IUPAC name [2-[4-(4-aminophenyl)butanoyloxy]-3-pentadecylphenyl] 4-(4-aminophenyl)butanoate
CAS Number	2016046-95-8
PubChem CID	89683272
UNII	LX6RQK5701
Chemical and physical data
Formula	C41H58N2O4
Molar mass	642.925 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCCCCCCCCCCCC1=C(C(=CC=C1)OC(=O)CCCC2=CC=C(C=C2)N)OC(=O)CCCC3=CC=C(C=C3)N
InChI InChI=1S/C41H58N2O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-20-35-21-17-22-38(46-39(44)23-15-18-33-25-29-36(42)30-26-33)41(35)47-40(45)24-16-19-34-27-31-37(43)32-28-34/h17,21-22,25-32H,2-16,18-20,23-24,42-43H2,1H3 Key:VLRZIRYGLUVGGU-UHFFFAOYSA-N

History

The compound is one of a class of compounds developed through University of Mississippi research^[5] by Mahmoud ElSohly, Waseem Gul, and Mohammad Khalid Ashfaq.^[1] Work on the compound is ongoing under Hapten Sciences,^[6] who licensed the university's research in 2010.^[5]

Evaluation as a drug candidate

The compound has been evaluated in two Phase I clinical trials, and a third Phase I randomized controlled trial, with a secondary objective of evaluating the effect of treatment on urishiol sensitivity, is due to be completed in December 2022.^{[7][needs update]}

See also

• Urushiol-induced contact dermatitis